We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Hexaell Biotech Stock

Invest in or calculate the value of your shares in Hexaell Biotech or other pre-IPO companies through EquityZen's platform.

Get Started
View More Companies

Hexaell Biotech Stock

Hexaell Biotech is a biopharmaceutical company focused on severe liver disease and cell therapy.

Invest NowSell Shares

About Hexaell Biotech Stock

Founded

2015

Industries

Software, Artificial Intelligence, Data and Analytics

Hexaell Biotechnology Co., Ltd is a start-up company pioneering in stem cell and artificial organ. The disruptive technologies were original published in "Nature. 475(7356):386-9" and "Cell Stem Cell. 14(3):370-84" from Chinese Academy of Sciences. Hexaell Biotechnology had licensed iHep and HiHep technologies from Chinese Academy of Sciences and developed medical devices of bio-artificial liver to replace liver function of human and cure liver failure diseases. Hexaell has finished pilot clinical studies in 6 liver failure patients in leading hepatopathy centers in China.

Hexaell Biotech Press Mentions

Stay in the know about the latest news on Hexaell Biotech

Hexaell Biotech advances liver program with $31 million raise

thepharmaletter • Feb 12, 2025

Hexaell Biotech Management

Leadership team at Hexaell Biotech

Executive Director/Founder

Hui Wu

Chief Executive Officer

Yu Chen

Locked Features

Join now and verify your accreditation status to gain access to:

  • Hexaell Biotech Current Valuation
  • Hexaell Biotech Stock Price
  • Hexaell Biotech Management
  • Available deals in Hexaell Biotech and all other companies with relevant Deal Offering documents
  • EquityZen's proprietary data and insights, which may include
    • Hexaell Biotech Cap Table and Funding History by Share Class and Liquidity Preferences
    • Hexaell Biotech Revenue and Financials
    • Hexaell Biotech Highlights
    • Hexaell Biotech Business Model
    • Hexaell Biotech Risk Factors
  • Hexaell Biotech Research Report from SACRA Research
Join Now

Trading Hexaell Biotech Stock

How to invest in Hexaell Biotech stock?

Accredited investors can buy pre-IPO stock in companies like Hexaell Biotech through EquityZen funds. These investments are made available by existing Hexaell Biotech shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Hexaell Biotech stock?

Shareholders can sell their Hexaell Biotech stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."

More Like Hexaell Biotech